Today: 21 May 2026
Browse Category

NYSE:JNJ 27 June 2025 - 29 November 2025

Johnson & Johnson Stock (JNJ) Near Record Highs: Earnings Momentum, Spin‑Off Plans and Talc Risks in 2025

Johnson & Johnson Stock (JNJ) Near Record Highs: Earnings Momentum, Spin‑Off Plans and Talc Risks in 2025

Johnson & Johnson shares closed at $206.92 on November 28, just below their 52-week high of $207.81. The stock is up about 43–47% year-to-date, far outpacing the S&P 500. Oncology sales rose 20.6% in the first nine months of 2025, reaching $18.5 billion. Analyst consensus remains broadly positive, with recent price targets mostly below current levels.
29 November 2025
··
Johnson & Johnson Stock (JNJ) Near Record Highs: Halda Deal, Spin‑Off Plans and Talc Risks on November 28, 2025

Johnson & Johnson Stock (JNJ) Near Record Highs: Halda Deal, Spin‑Off Plans and Talc Risks on November 28, 2025

Johnson & Johnson shares closed just below a 52-week high near $208 on November 28, giving the company a $500 billion market cap. The stock is up 17.6% over three months and 43% year-to-date, far outpacing the S&P 500. Recent moves include a $3.05 billion Halda Therapeutics acquisition and plans to spin off DePuy Synthes. Norway’s sovereign wealth fund has taken a multibillion-dollar stake.
28 November 2025
··
Johnson & Johnson (JNJ) Stock Today – November 26, 2025: 12‑Day Rally Pushes Shares Toward $500 Billion Valuation

Johnson & Johnson (JNJ) Stock Today – November 26, 2025: 12‑Day Rally Pushes Shares Toward $500 Billion Valuation

Johnson & Johnson shares traded near $207.11 Wednesday afternoon, just below their all-time high, putting the company’s market value around $498–500 billion. The stock has gained about 47% year-to-date, outpacing the S&P 500, and is on track for a record 13-day winning streak. November’s nearly 10% rise would mark its best month since 2021.
26 November 2025
·
Johnson & Johnson (JNJ) Stock on November 25, 2025: Ex‑Dividend Day, Options Surge and a $3 Billion Cancer Bet

Johnson & Johnson (JNJ) Stock on November 25, 2025: Ex‑Dividend Day, Options Surge and a $3 Billion Cancer Bet

Johnson & Johnson traded near $206 per share on Monday, just below its 12-month high, ahead of Tuesday’s key ex-dividend date for a $1.30 per share payout. The stock is up over 7% in November, outpacing the broader market. Options activity spiked Monday, with call volume jumping 468% to about 201,000 contracts. JNJ’s market cap stands just under $500 billion.
25 November 2025
···
Johnson & Johnson’s $3.05 Billion Halda Therapeutics Deal Signals New Oncology Push After Stelara Patent Cliff

Johnson & Johnson’s $3.05 Billion Halda Therapeutics Deal Signals New Oncology Push After Stelara Patent Cliff

Johnson & Johnson will acquire Halda Therapeutics for $3.05 billion in cash, expanding its oncology portfolio. Halda’s lead drug candidate targets advanced prostate cancer. The deal is expected to close in the coming months, pending regulatory approval. J&J faces declining Stelara sales as biosimilar competition increases.
17 November 2025
··
Bristol Myers Squibb (BMY) Shares Slide as Milvexian Heart Trial Halted After Interim Review – What Investors Need to Know Today (14 November 2025)

Bristol Myers Squibb (BMY) Shares Slide as Milvexian Heart Trial Halted After Interim Review – What Investors Need to Know Today (14 November 2025)

Bristol Myers Squibb and Johnson & Johnson have halted the Phase 3 Librexia ACS trial of milvexian in acute coronary syndrome after an interim review showed the drug was unlikely to meet its main efficacy goal. BMY shares fell following the announcement. No new safety issues were reported. The trial had aimed to enroll about 16,000 patients worldwide.
14 November 2025
···
Stocks Slip as Tech Wobble Returns; Layoffs Spike and Tariff Showdown Clouds Outlook — Stock Market Today (Nov. 6, 2025)

Stock Market Today (Nov. 11, 2025): Dow Closes at a Record as AI Shares Stumble; FTSE 100 Hits New High on BoE Cut Bets

The Dow Jones closed at a record 47,927.96 on Nov. 11, 2025, up 1.18%, while the Nasdaq fell 0.25% as Nvidia dropped nearly 3% after SoftBank revealed a $5.8 billion stake sale. The S&P 500 edged higher. In Europe, the FTSE 100 hit a record near 9,900, boosted by Vodafone’s first dividend increase in eight years and rising bets on Bank of England rate cuts.
11 November 2025
········
Stocks Slip as Tech Wobble Returns; Layoffs Spike and Tariff Showdown Clouds Outlook — Stock Market Today (Nov. 6, 2025)

Top 5 US Stocks to Buy Today (Nov. 7, 2025): CEG, NEE, XOM, JNJ, KKR — Navigating Shutdown Flight Cuts, the AI Selloff, and Energy’s Repricing

The FAA began cutting flights by up to 10% at 40 major US airports today, causing hundreds of cancellations and pressuring airline stocks. AI-linked tech shares slipped after a strong 2025 run, while crude oil fell to the low-$60s. Constellation Energy reported Q3 earnings and NextEra shares rose after a nuclear deal with Google. The federal shutdown is delaying key economic data releases.
7 November 2025
·······
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 25.10.2025

Intel shares have doubled year-to-date, driven by Q3 results and management’s outlook on process tech and data-center demand. Innodata jumped 4% in the latest session, with a 94% YTD gain and a P/E of 57.2, raising valuation questions. Johnson & Johnson is up 22% over the past year, with fair value estimates near $198, but faces litigation and pricing risks.
25 October 2025
···
J&J Makes Bold Move: Orthopedics Spin-Off (“DePuy Synthes”) Announced – 2025 Forecast Raised

J&J Makes Bold Move: Orthopedics Spin-Off (“DePuy Synthes”) Announced – 2025 Forecast Raised

Johnson & Johnson will spin off its $9.2 billion orthopedics business as DePuy Synthes within 18–24 months, its second major split since 2023. J&J beat Q3 2025 earnings estimates, raised its full-year revenue outlook to up to $93.9 billion, and saw shares rise 2% on Oct. 14. The move shifts J&J’s focus to higher-growth drug and device segments. CFO Joe Wolk said orthopedics innovation was “in better hands somewhere else.”
14 October 2025
·
Protagonist Therapeutics: Small Biotech Skyrockets on Buyout Buzz & Breakthrough Trials

Protagonist Therapeutics: Small Biotech Skyrockets on Buyout Buzz & Breakthrough Trials

Protagonist Therapeutics shares surged over 30% to nearly $89 on October 10, 2025, after reports that Johnson & Johnson is in talks to acquire the company. Trading was briefly halted due to volatility. The company, valued at about $5.4 billion, recently announced positive trial results for its lead drugs and secured major partnerships with J&J and Takeda.
11 October 2025
·····
Massive Moves: Record Deals, FDA Wins & Crypto Mania Propel Top Stock Gainers (Sep 29, 2025)

Record Rally Stalls as Fed Cut Bets Soar and Earnings Loom

The S&P 500 and Nasdaq 100 hit record highs this week before retreating Thursday; U.S. stock futures edged up 0.1% early Friday. Fed funds futures now price in a 95% chance of a rate cut in October. Some economic data releases are delayed by the ongoing federal shutdown. Major banks and tech firms begin reporting Q3 earnings next week.
10 October 2025
·········
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly will invest $5 billion to build a 200,000-square-foot drug manufacturing plant in Goochland County, Virginia, creating 650 permanent jobs and 1,800 construction jobs. The facility will produce active pharmaceutical ingredients for cancer and autoimmune treatments. The project is part of Lilly’s $27 billion U.S. expansion plan. Virginia approved over $10 million in incentives to secure the site.
16 September 2025
·······
Global Biotech & Health Roundup: Breakthrough Drugs, Big Deals & Policy Shifts (Aug 21–22, 2025)

Global Biotech & Health Roundup: Breakthrough Drugs, Big Deals & Policy Shifts (Aug 21–22, 2025)

The FDA approved Ionis’s Dawnzera for hereditary angioedema and Precigen’s Papzimeos for recurrent respiratory papillomatosis, marking a first for viral immunotherapy. Gilead’s Kite Pharma will acquire Interius BioTherapeutics for $350 million. Johnson & Johnson announced a $2 billion biomanufacturing facility in North Carolina. Apollo Hospitals’ managing director sold a $170 million stake in a major block trade.
22 August 2025
·····
Robotics and Automation Trends 2025: Industry Breakthroughs and Market Outlook (Updated: June 27th, 2025)

Robotics and Automation Trends 2025: Industry Breakthroughs and Market Outlook (Updated: June 27th, 2025)

New industrial robot installations reached $16.5 billion in 2024, with over 4.28 million robots active in factories worldwide. Asia led 2023 installations, accounting for 70%, and China alone made up 51%. Amazon operated about 800,000 mobile robots in its fulfillment centers by 2024. Global robot density hit 150 per 10,000 manufacturing workers in 2023, with South Korea surpassing 1,000.
28 June 2025
········
Top Biotechnology and Health Tech Trends in 2025: Mid-Year Update and Forecast (Updated: June 27th, 2025)

Top Biotechnology and Health Tech Trends in 2025: Mid-Year Update and Forecast (Updated: June 27th, 2025)

The FDA approved Abeona’s Zevaskyn, the first cell-based gene therapy for RDEB, in April 2025, with launch set for Q3 at $3.1 million. Vertex’s CRISPR therapy Casgevy generated $2 million in Q3 2024. Novo Holdings acquired Catalent for $16.5 billion in January 2025 to secure GLP-1 drug manufacturing. Johnson & Johnson bought Intra-Cellular Therapies for $14.6 billion, expanding its neuroscience portfolio.
27 June 2025
···········
1 … 6 7 8

Stock Market Today

  • Crude Oil Surge Boosts Ethanol and Sugar Prices Amid Production Shifts
    May 21, 2026, 2:36 PM EDT. Crude oil prices rose over 2%, driving gains in ethanol and sugar markets. July New York sugar futures climbed 0.95%, supported by strong crude oil. Higher oil values encourage sugarcane mills to produce more ethanol, reducing sugar output. The International Sugar Organization forecasts a record 182 million metric tons (MMT) sugar crop for 2025/26 but anticipates a drop to 180 MMT in 2026/27, with a potential deficit due to El Niño impacts on key producers like India and Thailand. Brazil's sugar production estimates are lowering amid increased ethanol focus, with Citigroup projecting 39.5 MMT for 2026/27, below official numbers. India's export ban and production shifts contribute to tightening supplies. Market watchers also highlight significant export growth from Thailand, adding complexity to price dynamics.

Latest articles

Sirius XM stock nears new highs as traders look at audio strategy

Sirius XM stock nears new highs as traders look at audio strategy

21 May 2026
Sirius XM shares rose 6.8% to $28.90 by 2:07 p.m. EDT Thursday, outpacing major U.S. indexes. The rally followed CFO Zac Coughlin’s investor conference appearance and news of a renewed multi-year NASCAR broadcast deal. First-quarter subscriber losses were smaller than expected, and revenue topped forecasts. Volume reached 4.8 million shares, with a market value near $9.8 billion.
KEEL Surges as Investors Back Keel’s AI Data Center Plans

KEEL Surges as Investors Back Keel’s AI Data Center Plans

21 May 2026
Keel Infrastructure shares jumped 7.1% to $4.53 Thursday, nearing a 52-week high, as investors bet on its pivot from crypto mining to AI-focused power infrastructure. Trading volume reached 22.31 million shares, below average. The company reported a wider net loss of $145.35 million for the March quarter on lower revenue and warned its transformation faces risks tied to permits, costs, and competition.
SoFi Stock Treads Water as Traders Keep an Eye on Next Move

SoFi Stock Treads Water as Traders Keep an Eye on Next Move

21 May 2026
SoFi Technologies shares fell 0.2% to $15.66 in early trading Thursday, underperforming tech peers as investors weighed strong first-quarter results against concerns over rates and credit risk. The company reported record loan originations of $12.2 billion and net income of $166.7 million, but kept its 2026 profit outlook unchanged after April’s earnings, disappointing some analysts.
Go toTop